StockNews.AI
GHRS
StockNews.AI
200 days

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

1. GHRS to update on Phase 2b trial results for GH001. 2. Conference call scheduled for February 3, 2025, at 8 a.m. EST. 3. GH001 showed 87.5% ultra-rapid remission in prior trials. 4. Focus on treatment-resistant depression provides significant market potential. 5. Company aims to transform psychiatric disorder treatment approach.

3m saved
Insight
Article

FAQ

Why Bullish?

The high remission rate in prior trials suggests strong market interest.

How important is it?

Key updates on drug trials are critical for biopharma companies like GHRS.

Why Short Term?

Upcoming trial updates can quickly affect investor sentiment and stock movement.

Related Companies

TRDGH001
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). About GH001 Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today. Investor RelationsJulie RyanGH Research PLCinvestors@ghres.com

Related News